FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences' Luveniq NDA
Links shared publicly online about this topic.
- 1,175total visits
FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences' Luveniq NDA
Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application (NDA) for Luveniq" (oral voclosporin) for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye on June 28, 2010.
View full resource at news-medical.net
Tags: Dermatology, Eye, Drug, FDA, Ophthalmology
Most Recently Shared on May 12, 2010 at 7:10 am By:
FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences’ Luveniq NDA: Lux Biosciences... http://bit.ly/bFVc4x
FDA Advisory Committee To Review Lux Biosciences' Uveitis Candidate Luveniq™
medicalnewstoday.com — “Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application” View full resource at medicalnewstoday.com
Most Recently Shared on May 13, 2010 at 3:12 am By:
FDA Advisory Committee To Review Lux Biosciences' Uveitis Candidate Luveniq™ http://mnt.to/3Cx6 #eyehealth
Advertisement
